Can ACEI/ARB prevent the cardiotoxicity caused by chemotherapy in early-stage breast cancer?—a meta-analysis of randomized controlled trials

BACKGROUND: Administration of anthracycline-based chemotherapy with or without trastuzumab is recognized as standard care for breast cancer, but it is associated with a decline in left ventricular ejection fraction (LVEF). Angiotensin-converting enzyme inhibitors (ACEI)/angiotensin II receptor block...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Haoran, Yao, Litong, Wang, Mozhi, Wang, Mengshen, Li, Xinyan, Sun, Xiangyu, Yu, Xueting, Guo, Jingyi, Li, Xiang, Xu, Yingying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799108/
https://www.ncbi.nlm.nih.gov/pubmed/35117309
http://dx.doi.org/10.21037/tcr-20-1869

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799108/
https://www.ncbi.nlm.nih.gov/pubmed/35117309
http://dx.doi.org/10.21037/tcr-20-1869

Ejemplares similares